Navigation Links
XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
Date:10/22/2007

ificity about their questions and the potential impact, if any, on our timeline, we will provide an update."

The company is also reiterating guidance that it expects to commercialize Custom NX in Europe in the second half of 2008.

About the CUSTOM Trials

The CUSTOM I trial is a 30-patient first-in-man study designed to evaluate the preliminary safety and feasibility of in-situ stent customization. CUSTOM I's positive eight-month clinical results have been sustained at two years with no new MACE events, zero restenosis and no late stent thrombosis.

The CUSTOM II trial is a 100-patient study designed to evaluate the safety and efficacy of Custom NX for the treatment of long and multiple lesions. Of the 100 patients enrolled, 69 patients were enrolled in the long-lesion arm, and 31 patients were enrolled in the two-lesion arm of the study. CUSTOM II enrolled one of the most difficult to treat patient populations ever studied in a DES trial. In the CUSTOM II patient population, the average vessel diameter was 2.57mm and the average lesion length was 28.7mm. Twenty-six percent of the study participants were diabetic. The percentage of patients with ACC/AHA lesion grade B2 or C was 65.1 percent. CUSTOM II's six-month clinical results have been sustained at one year. The target lesion revascularization rate remained constant at four percent, with no new MACE events, and no late stent thrombosis.

The company's CUSTOM III clinical trial completed enrollment in July as previously announced, and the company expects the first available data to be presented at the 2008 Euro-PCR meeting.

About the Custom NX(R) DES System

Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent de
'/>"/>

SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014   ... today the appointment of J. Patrick Ravenel ... years of enterprise software and systems experience and a ... Fortune 500 companies. "Patrick has been ... class software and systems and is known industry-wide for ...
(Date:10/1/2014)... , Oct. 1, 2014  SI-BONE, Inc., a medical device ... ® a minimally invasive surgical (MIS) device indicated for ... announced the expansion of its European operations with the formation ... Schaber as General Manager, Germany.  Mr. Schaber will join ... of Europe , Middle East ...
(Date:10/1/2014)... , Switzerland , October 1, 2014 ... in Clinical Genomics and Next Generation Sequencing (NGS) data ... clinicians to run full cystic fibrosis analysis in a ... identification and characterisation of all types of variants in ... Until now, it has not been possible ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... RRY Publications LLC today announced the presenter line-up for ... is slated to bring together the largest gathering of ... New York.  Participants will learn about investment opportunity in ... the growing market potential for the industry.   ...
... Md., Feb. 7, 2011 Today the U.S. Food and ... to conduct postmarket surveillance studies to determine the length of ... pain or other reasons. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... to the temporal bone in the skull. A person may ...
Cached Medicine Technology:6th Annual New York Stem Cell Summit Presenters Announced 2FDA Orders Postmarket Surveillance of Certain TMJ Implants 2FDA Orders Postmarket Surveillance of Certain TMJ Implants 3
(Date:10/1/2014)... ST. LOUIS, MO (PRWEB) October 01, 2014 ... up for Castlewood Eating Disorder Treatment Center’s first ever charity ... provides grants for people with eating disorders who cannot afford ... Fox Run Golf Club in Eureka, Mo. , The ... time at noon. A reception and award dinner will begin ...
(Date:10/1/2014)... Maine (PRWEB) October 01, 2014 Between ... disorders in the U.S., according to figures from the ... Related Diseases Association (AARDA), and many of them have ... chance of having undiagnosed celiac disease. Gluten Free ... raise awareness of undiagnosed celiac disease by publishing a ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 NoteSwift Inc., ... EHR versions 10.0, 12.1 and 13.0. NoteSwift is the ... as commands to navigate and document clinical information at ... provider spends creating a patient note by more than ... of the major pain points providers state impedes EHR ...
(Date:10/1/2014)... IL (PRWEB) October 01, 2014 On ... two Chicago-based finalists in the Martha Stewart American Made ... small businesses across the country in the fields of ... to be recognized as a finalist in the MSAMAs, ... inspiring products that are improving local communities and changing ...
(Date:10/1/2014)... Deland, Florida (PRWEB) October 01, 2014 ... to promote awareness and early detection plans while raising ... to support Breast Cancer Awareness Month in ... Water also wants to promote the importance of having ... contaminated drinking water may be linked to certain forms ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2
... /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: PMD; PREMF.pk) ("PreMD" ... quarter of fiscal 2008 ended,September 30, 2008 ("Q3 2008")., ... the PREVU* appeal is being reviewed by the ... the agreement with AstraZeneca has been terminated; ...
... BPA might lessen chances of successful pregnancy, research suggests ... a controversial chemical used to harden plastic packaging for ... report. , Bisphenol A (BPA) could hurt the chances ... embryos to attach to the uterus, according to presentations ...
... Stem Cell ... Biology Research, ST. ... with AlphaGenix, Inc., a,leading developer and manufacturer of products for basic ... of,AlphaGenix-developed antibodies and research tools for the fields of,regenerative medicine and ...
... socioeconomic factor influencing outcomes, study finds , , THURSDAY, Nov. ... die from inoperable non-small cell lung cancer than women, ... most important factor influencing overall survival of patients with ... of researchers in six U.S. cities studied 1,365 patients ...
... Ga., Nov. 13 On behalf of its 24,965,members ... called for the public release of the details related ... Dougherty County Commission,on changes to the health care plan ... to the county commissioners expressing concerns and,asking questions about ...
... Popular Ribbon Campaign Moves from Bumpers to Blogs , ... San Mateo, ... the Alzheimer,s Association teamed up in the fight against Alzheimer,s, ... media campaign to spread awareness of this growing epidemic. The Purple Ribbon ...
Cached Medicine News:Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 2Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 3Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 4Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 5Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 6Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 7Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 8Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 9Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 10Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 11Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 12Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 13Health News:Chemical in Plastics May Cause Fertility Problems 2Health News:Chemical in Plastics May Cause Fertility Problems 3Health News:Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc. 2Health News:Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc. 3Health News:Lung Cancer May Be Deadlier for Men 2Health News:CAGW Questions Healthcare Plan Options Presented to the Dougherty County Commission 2Health News:Caring.com and Alzheimer's Association Use Social Media to Help Spread Awareness for the Nation's Sixth Leading Cause of Death 2Health News:Caring.com and Alzheimer's Association Use Social Media to Help Spread Awareness for the Nation's Sixth Leading Cause of Death 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: